Health
Should you get another COVID booster? Guidelines are changing
|
|
The World Health Organization (WHO) on Tuesday said it no longer “routinely recommends” additional COVID-19 vaccine boosters for medium or low-risk people, but one Canadian doctor is warning the “advice isn’t probably the best.”
The updated roadmap from WHO outlines three priority-use groups for COVID-19 vaccination: high, medium and low, and is designed to prioritize vaccines for those at greater risk of the disease.
The WHO recommended additional booster doses for high-priority groups such as older people, immunocompromised people of all ages, front-line health workers and pregnant people. But for those who fall under the low and medium-risk group, WHO did not recommend additional COVID-19 boosters, citing “low public health returns.”
The WHO’s updated guidance comes just weeks after Canada’s National Advisory Committee on Immunization (NACI) last updated its guidelines on boosters.
“Society is caught between wanting this whole thing to be over and still reconciling that it’s still a threatening problem out there,” Dr. Kashif Pirzada, a Toronto emergency room doctor, told Global News.
“We see plenty of people with just two vaccines who get a fairly brutal illness…the most severe your illness, the more chances you’ll have long-term lingering symptoms. So I think they didn’t really factor that in is that it’s still out there,” he said.
Despite the persistent presence of the highly contagious Omicron variant in Canada, COVID-19 is not expected to surge in the coming months as hospitalizations and deaths remain stable, federal health officials said earlier this month.
On March 10, Canada’s chief public health officer, Dr. Theresa Tam, said that COVID-19 activity has reached a “relatively steady state,” in the country and “we may not see any major waves in the coming months as we prepare for a potential fall and winter surge.”
Because the country is seeing a decrease in deaths relating to COVID-19 infection, Dr. Susy Hota, medical director of infection prevention and control at the University Health Network, said she agrees with WHO’s recommendations.
“I think from a global perspective it makes a lot of sense and probably also makes sense from a Canadian perspective,” she said.
“We know that especially in Canada, younger people have a higher level of hybrid immunity. So having had vaccine doses, but then also prior infections…may offer better protection overall,” she said.
Canada — and the rest of the world — seems to be shifting into a new way of dealing with the disease, she added, which is transitioning into something “more sustainable” for the long term, such as focusing on high-risk individuals.
In terms of where Canada stands on vaccine boosters, Pirzada said there has been little messaging out there, other than a spring shot for high-risk individuals.
Canada’s current COVID vaccine recommendations
NACI’s latest guidance on COVID-19 vaccines on March 3 recommended that people facing a high risk of serious illness should get another COVID-19 booster in the spring.
The committee advises all Canadians five years old and up should get immunized against COVID-19 with a full primary series of vaccines. For most people, a primary series is two doses of a COVID-19 vaccine, at a recommended interval of eight weeks apart.
NACI states that “children 6 months to under 5 years of age may be immunized with a primary series of an authorized mRNA vaccine.”
NACI further recommends a booster dose six months after the last dose of a primary course for everyone aged five years old and up.
‘Make a case’ to get booster
Because the most recent NACI guideline is only for high-risk individuals, Pirzada worries, like the WHO, NACI is not taking into account long-term COVID-19 symptoms, which can happen in healthy young people too.
“And the farther out you are from your boosters or from your vaccines, the more chances of having a much more severe course of illness,” he said.
His advice for Canadians is to get a booster if you are six to 12 months out of your vaccine, especially if you’re going to travel or be around large crowds.
If you don’t fall under the high-risk category and want to get boosted, Pirzada said “to make a case” to a physician or pharmacist saying, you’re worried about COVID-19 infection and want a booster.
“Boosters will protect you for three months from infection. That’s pretty good…protection for three months. If you are at high-risk settings in that time where you want to really have fun, that’s not a bad idea,” he added.
Hota believes that low-risk individuals, mainly those who feel nervous about travelling without a booster, should modify their behaviour “if they are concerned.”
The goal of vaccines, she said, is to reduce the risk of severe illness, and if an individual has a very low risk of getting severely sick from COVID-19 (because of hybrid immunity), “it’s probably not going to be offering you that much more protection.”
She stressed that vaccines will have the greatest impact on those at the highest risk.
According to Health Canada, a booster dose of a BA.4/5 bivalent mRNA COVID-19 vaccine “provides increased protection against both symptomatic disease and hospitalization, compared to those who did not receive a bivalent booster dose but received at least two previous doses of original monovalent vaccines in the past.”
— with files from Reuters
|
|
The USask Global Institute for Water Security wastewater survey for Prince Albert shows that the COVID-19 viral RNA load in Prince Albert’s has decreased by 46.5 per cent.
This was after there was a single decrease in last week’s report.
The number is based on averages of three individual daily measurements in this reporting period up to May 22 which are then compared to the weekly average of the previous week.
This week’s viral load of approximately 10,000 gene copies / 100 mL SARS-CoV-2 is the 85th-highest value observed during the pandemic.
This concentration of viral particles is considered Low because it is below the range and regarded as low in Prince Albert.
This week’s viral RNA load indicates that the SARS-CoV-2 infections in Prince Albert are reducing.
Whole genome sequencing confirmed the presence of BQ.1, BQ.1.1, BQ.1.1.4, BQ.1.18, XBB.1.5, BA.5.2.1 and BE.1.1 in earlier samples; which have S:Y144del, S:R346T, S:K444T, S:N460K mutations associated with immune escape. In addition, the sequences of the most recently collected sample relative to the previously collected samples indicate the level of presence of BA.2 and BA.5 in Prince Albert’s wastewater to be 94 per cent and 78 per cent stable respectively.
All data has been shared with Saskatchewan health authorities.
USask and Global Water Futures researchers are using wastewater-based epidemiology to monitor for SARS-CoV-2 (the virus causing COVID-19) in Saskatoon, Prince Albert and North Battleford wastewater, providing early warning of infection outbreaks. This work is being done in partnership with the Saskatchewan Health Authority, Public Health Agency of Canada, City of Saskatoon, City of Prince Albert and City of North Battleford.
This variant tracking data should be seen merely as an indicator of trends which need to be verified using sequencing technology through the Public Health Agency of Canada. Because individuals are at varying stages of infection when shedding the virus, the variant levels detected in sewage are not necessarily directly comparable to the proportion of variant cases found in individual swab samples confirmed through provincial genetic sequencing efforts.
editorial@paherald.sk.ca
Health
Just when we were starting to see COVID and RSV rates drop this spring, another type of virus contributed to a spike in respiratory infections
|
|
- Human metapneumovirus spiked this spring as cases of COVID and RSV fell.
- According to the CDC, 19.6% of antigen tests and nearly 11% of PCR tests for HMPV, were positive in the US in early March.
- Symptoms of HMPV include cough, fever, nasal congestion, and shortness of breath.
Cases of another type of respiratory virus have spiked this spring, just as COVID-19 and RSV rates were finally falling in the US.
According to the CDC, 19.6% of antigen tests and nearly 11% of PCR tests for human metapneumovirus, or HMPV, were positive in the US in early March.
The nearly 11% of positive PCR cases is up 36% since before the COVID-19 pandemic when PCR tests for HMPV were coming back with a rate of 7% positivity, according to the CDC.
In contrast, COVID-19 cases were down nearly 30% at the beginning of March, according to the World Health Organization, and the number of people being hospitalized for RSV was down to 1.2 people per 100,000 in March from 4.5 people per 100,000 in January, according to the CDC.
Symptoms of HMPV include cough, fever, nasal congestion, and shortness of breath, according to the CDC. The symptoms could progress into bronchitis, pneumonia, or other similar viruses that cause upper and lower respiratory infections.
The CDC said some might be sicker for longer than others, and the duration of the virus depends on the severity, but for the most part, is similar in length to other respiratory infections caused by viruses.
The virus is spread by coughs and sneezes, close personal contact, and touching surfaces infected with the virus, then touching the mouth, nose, or eyes.
According to CNN, there’s no vaccine for HMPV, nor is there an antiviral drug to treat it.
Health
Just when we were starting to see COVID and RSV rates drop this spring, another type of virus contributed to a spike in respiratory infections
|
|
- Human metapneumovirus spiked this spring as cases of COVID and RSV fell.
- According to the CDC, 19.6% of antigen tests and nearly 11% of PCR tests for HMPV, were positive in the US in early March.
- Symptoms of HMPV include cough, fever, nasal congestion, and shortness of breath.
Cases of another type of respiratory virus have spiked this spring, just as COVID-19 and RSV rates were finally falling in the US.
According to the CDC, 19.6% of antigen tests and nearly 11% of PCR tests for human metapneumovirus, or HMPV, were positive in the US in early March.
The nearly 11% of positive PCR cases is up 36% since before the COVID-19 pandemic when PCR tests for HMPV were coming back with a rate of 7% positivity, according to the CDC.
In contrast, COVID-19 cases were down nearly 30% at the beginning of March, according to the World Health Organization, and the number of people being hospitalized for RSV was down to 1.2 people per 100,000 in March from 4.5 people per 100,000 in January, according to the CDC.
Symptoms of HMPV include cough, fever, nasal congestion, and shortness of breath, according to the CDC. The symptoms could progress into bronchitis, pneumonia, or other similar viruses that cause upper and lower respiratory infections.
The CDC said some might be sicker for longer than others, and the duration of the virus depends on the severity, but for the most part, is similar in length to other respiratory infections caused by viruses.
The virus is spread by coughs and sneezes, close personal contact, and touching surfaces infected with the virus, then touching the mouth, nose, or eyes.
According to CNN, there’s no vaccine for HMPV, nor is there an antiviral drug to treat it.
Read the original article on Insider
Uganda’s president signs into law anti-gay legislation with death penalty in some cases
Alberta votes in the strangest — and closest — election in its political history
Alberta voters await election results as polls close across province
-
News20 hours agoThe Hidden Struggles: Uncovering the Reality of Being Black in Canada
-
Economy21 hours ago
Lira hits record low, but stocks rise after Erdogan win in Turkey
-
Business21 hours ago
Halifax condo residents face obstacles trying to go green with solar panels
-
Media18 hours ago
Russia says U.S. Senator should say if Ukraine took his words out of context
-
Health20 hours ago
B.C. initiative aims to expand genetic screening for Ashkenazi Jewish people at risk of hereditary cancers
-
News17 hours ago
More Canadian companies adopt ‘stay interviews’ amid push to retain staff
-
Real eState19 hours ago
BCFSA rules on real estate agent’s $50K loan to client
-
Health23 hours ago
Coming to Terms with My Baby’s Food Allergies
